**3. Conclusions**

The current review has summarized TMPs commonly used in the treatment of respiratory symptoms and diseases, which possess potential adjuvant, prophylactic, and therapeutic properties against SARS-CoV-2 including *Acacia Senegal*, *Artemisia afra*, *Aspalathus linearis*, *Clerodendrum splendens*, *D. batatas* decne*, E. purpurea*, *Hypoxis hemerocallidea*, *Xysmalobium undulatum*, *Tinospora crispa*, *Sutherladia frutescens,* and *Z. officinale*. Secondary metabolites present in selected TMPs are responsible for the pharmacological activities of these medicinal plants. TMPs identified by molecular docking analysis should be investigated experimentally as potential SARS-CoV-2 treatment. Further studies are warranted to isolate and test secondary metabolites with inhibitory properties against SARS-CoV-2. Safety and efficacy profiles of these TMPs must be explored *in vitro* and *in vivo*. Animal studies and human clinical trials are required for further testing of these TMPs before recommendations to use in COVID-19 patients.
